LAG3 Expression in Triple Negative Breast Cancer

Clinical trial NCT06259162 · RECRUITING

Trial details

NCT number: NCT06259162
Sponsor: Samsung Medical Center
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Immune Checkpoint Inhibitor

Start date: 2022-11-18
Primary completion: 2025-07-01
Enrollment: 128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.